ArticleAnnals of clinical microbiology and antimicrobials2015
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.
Article in Annals of clinical microbiology and antimicrobials, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Catalase: A Potential Pharmacologic Target for Hydrogen Peroxide in the Treatment of COVID-19.Current topics in medicinal chemistry · 2024Pooled it
- Off-label and repurposed use of disulfiram beyond alcohol dependence: A systematic review of clinical and preclinical evidence.iScience · 2026Article
- Otilonium Bromide Exhibits Potent Antifungal Effects by Blocking Ergosterol Plasma Membrane Localization and Triggering Cytotoxic Autophagy in Candida Albicans.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Accumulation of endogenous free radicals is required to induce titan-like cell formation inmBio · 2024Article
- Identifying Potential Molecular Targets in Fungi Based on (Dis)Similarities in Binding Site Architecture with Proteins of the Human Pharmacolome.Molecules (Basel, Switzerland) · 2023Article
- Luciferase-Based High-Throughput Screen with Aspergillus fumigatus to Identify Antifungal Small Molecules.Methods in molecular biology (Clifton, N.J.) · 2023Article
- Disulfiram: A Repurposed Drug in Preclinical and Clinical Development for the Treatment of Infectious Diseases.Anti-infective agents · 2022Article
- Impeding Virulence of Candida albicans by Candesartan and Domperidone.Current microbiology · 2021Article
- Current and promising pharmacotherapeutic options for candidiasis.Expert opinion on pharmacotherapy · 2021Article
- Micafungin Inhibits Dengue Virus Infection through the Disruption of Virus Binding, Entry, and Stability.Pharmaceuticals (Basel, Switzerland) · 2021Article
- One Century of Study: What We Learned aboutJournal of fungi (Basel, Switzerland) · 2021Review
- Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium.Antibiotics (Basel, Switzerland) · 2020Review
- Antifungal Drug Repurposing.Antibiotics (Basel, Switzerland) · 2020Article
- Antifungal drug screening: thinking outside the box to identify novel antifungal scaffolds.Current opinion in microbiology · 2020Review
- Identification of Bithionol, Dichlorophen, and Miconazole as Antibacterial Agents againstACS omega · 2020Article
- Repurposing Clinically Approved Drugs for the Treatment ofACS omega · 2020Article
- Screening Repurposing Libraries for Identification of Drugs with Novel Antifungal Activity.Antimicrobial agents and chemotherapy · 2020Review
- Fluconazole analogues with metal-binding motifs impact metal-dependent processes and demonstrate antifungal activity in Candida albicans.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2020Article
- Current Antimycotics, New Prospects, and Future Approaches to Antifungal Therapy.Antibiotics (Basel, Switzerland) · 2020Review
- Identification of Off-Patent Drugs That Show Synergism with Amphotericin B or That Present Antifungal Action against Cryptococcus neoformans andAntimicrobial agents and chemotherapy · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe high cost and prolonged timeline of new drug discovery and development are major roadblocks to creating therapies for infectious diseases. Candida albicans is an opportunistic fungal pathogen that is the most common cause of fatal fungal infections in humans and costs $2-4 billion dollars to treat in the US alone.
methodsTo accelerate drug discovery, we screened a library of 1581 existing FDA approved drugs, as well as drugs approved abroad, for inhibitors of C. albicans. The screen was done on YPD yeast growth media as well as on the serum plate assay developed in this study.
resultsWe discovered that fifteen drugs, all which were originally approved for treating various infectious and non-infectious diseases, were able to kill Candida albicans. Additionally, one of those drugs, Octodrine, displays wide-spectrum anti-microbial activity. Compared to other selected anti-Candida drugs, Octodrine was shown to be one of the most effective drugs in killing serum-grown Candida albicans without significantly affecting the survival of host macrophages and skin cells.
conclusionsThis approach is useful for the discovery of economically viable new therapies against infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.